Pfizer, once a pandemic success story, is now facing challenges with declining sales and increased competition. Stock dropped 15.5% in the last year, sparking investor concerns about the company’s future. Despite a revenue decline in Q1 2025, Pfizer saw bottom-line growth driven by cost controls and favorable tax resolutions.

CEO Albert Bourla highlighted Pfizer’s transformation efforts, focusing on high-potential assets in oncology, vaccines, and internal medicine. The company aims to achieve $7.7 billion in net savings by 2027 to reinvest in pipeline development. With 108 clinical programs in progress, 2025 could be a pivotal year for Pfizer’s pipeline milestones, especially in oncology.

Notable candidates in Pfizer’s pipeline include sasanlimab for bladder cancer and Padcev for urothelial cancer, showing significant promise. The company’s antibody-drug conjugates have the potential to change the standard of care for lung cancer. Pfizer is also investing in vaccines to solidify its position in pneumococcal prevention.

Pfizer remains focused on long-term shareholder value, offering a 7% dividend yield. Wall Street analysts rate Pfizer stock as a “Moderate Buy,” with an average price target suggesting a 12.7% upside potential. Despite recent struggles, Pfizer’s cost-cutting and pipeline investments position it for future growth in key therapeutic areas.

Investors evaluating Pfizer should consider its reset as an entry point, with the stock trading 22% lower than its 52-week high. While Pfizer shows promise in restructuring and pipeline development, the stock’s revival hinges on the generation of new revenue streams from its maturing pipeline.

Read more at Yahoo Finance: This Blue-Chip Stock Is 20% Off Its Highs. Should You Buy the Dip?